Drug Trial Radar · NCT07652515
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer
Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Aug 17, 2026
Primary completion
Aug 30, 2030
Study completion Aug 30, 2030
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jun 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety of dostarlimab in combination with carboplatin and paclitaxel followed by monotherapy when administered as a first-line treatment in advanced or recurrent endometrial cancer (EC).
Conditions
- Neoplasms, Endometrial
Interventions
DostarlimabDrug
Dostarlimab will be administered.
CarboplatinDrug
Carboplatin will be administered.
PaclitaxelDrug
Paclitaxel will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Grade 3 or greater treatment-emergent adverse events (TEAEs) up to Week 49Time frame: Up to Week 49
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.